Matinas BioPharma Reports 2017 First Quarter Financial Results and Provides Corporate Update
– Announced positive topline data from initial study in Phase 1 program for MAT2501 – – Company on track to report interim Phase 2 data of MAT2203 for mucocutaneous candidiasis and topline data of MAT2203 Phase 2 study for vulvovaginal candidiasis in June …